Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

Circulation. 1999 Jan;99(1):168-77. doi: 10.1161/01.cir.99.1.168.
No abstract available

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / therapy*
  • Coitus / physiology
  • Drug Interactions
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / therapeutic use*
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / physiopathology
  • Humans
  • Male
  • Piperazines / adverse effects
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use*
  • Purines
  • Sildenafil Citrate
  • Sulfones

Substances

  • Enzyme Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate
  • 3',5'-Cyclic-GMP Phosphodiesterases